Search Results

Arsenal Medical today announced enrollment of the first patient with the company’s investigational NeoCast™ embolic biomaterial.

Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.

Arsenal Biosciences, Inc. today announced that the first patient has been dosed with AB-2100 in a multi-center, open-label Phase 1/2 clinical trial for patients with clear-cell renal cell carcinoma (ccRCC).

Arsenal Biosciences, Inc. (ArsenalBio) today announced that Ken Drazan, MD, the company’s Chairman and Chief Executive Officer, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:30 a.m. PT.

Fortrea, a leading global contract research organization, announced it has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical and Fortrea Patient Access businesses, to Arsenal Capital Partners, a leading private equity firm specializing in building market-leading, technology-rich healthcare companies.

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Society of Gene + Cell Therapy (ASGCT) annual meeting in Baltimore, Md., May 7-11, 2024.

Arsenal Biosciences, Inc. today announced that it will present preclinical data on its integrated circuit T cell therapies, AB-1015 and AB-2100, in an oral abstract session and three posters at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Los Angeles, Calif., May 16-20, 2023.